Six-month compliance with antidepressant medication in the treatment of major depressive disorder

被引:55
|
作者
Demyttenaere, Koen [1 ]
Adelin, Albert [2 ]
Patrick, Mesters [3 ]
Walthere, Dewe [3 ]
Katrien, De Bruyckere
Michele, Sangeleer
机构
[1] Univ Hosp Gasthuisberg, Dept Psychiat, B-3000 Louvain, Belgium
[2] Univ Hosp, Dept Biostat, Ghent, Belgium
[3] Eli Lilly Mt St Guibert, European Dev Ctr, Mont St Guibert, Belgium
关键词
antidepressants; compliance; major depressive disorder;
D O I
10.1097/YIC.0b013e3282f1c1d8
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The investigation of compliance in patients with major depressive disorder (in drop-outs versus completers and in first episode versus recurrent episode patients). A total of 85 outpatients with major depressive disorder were followed for 6 months. Different dimensions of compliance were investigated: drop-outs versus completers and their medication adherence (with electronic monitoring). General linear mixed models were applied to examine the time courses of adherence. Drop-out rates were higher in younger patients and in patients with a lower initial depression severity. The adherence during 6 months of treatment with selective serotonin reuptake inhibitors was above 80 in 70% of the patients. The adherence decreased by 2.5% per month and decreased more than three times more rapidly in drop-outs (from baseline to time of drop-out). A medical visit resulted in a temporary increase in pill intake. General linear mixed model analysis showed that the predicted outcome was worse in drop-outs than in completers and worse in recurrent episode patients than in first episode patients (the former showing a higher adherence). Adherence decreases with time during 6 months of treatment with antidepressants and is influenced by demographic and clinical variables. Completers show a higher adherence than drop-outs. The outcome was worse in recurrent episode patients than first episode patients although they had a higher adherence.
引用
收藏
页码:36 / 42
页数:7
相关论文
共 50 条
  • [21] The efficacy profile of vilazodone, a novel antidepressant for the treatment of major depressive disorder
    Reed, Carol R.
    Kajdasz, Daniel K.
    Whalen, Heidi
    Athanasiou, Maria C.
    Gallipoli, Susan
    Thase, Michael E.
    CURRENT MEDICAL RESEARCH AND OPINION, 2012, 28 (01) : 27 - 39
  • [22] Impact of medical comorbid disease on antidepressant treatment of major depressive disorder
    Iosifescu D.V.
    Bankier B.
    Fava M.
    Current Psychiatry Reports, 2004, 6 (3) : 193 - 201
  • [23] An investigation of EEG, genetic and cognitive markers of treatment response to antidepressant medication in patients with major depressive disorder: A pilot study
    Spronk, D.
    Arns, M.
    Barnett, K. J.
    Cooper, N. J.
    Gordon, E.
    JOURNAL OF AFFECTIVE DISORDERS, 2011, 128 (1-2) : 41 - 48
  • [24] Antidepressant dose reduction and the risk of relapse in major depressive disorder
    Papakostas, George I.
    Perlis, Roy H.
    Seifert, Cheryl
    Fava, Maurizio
    PSYCHOTHERAPY AND PSYCHOSOMATICS, 2007, 76 (05) : 266 - 270
  • [25] Keywords: Major depressive disorder Antidepressant treatment Noradrenergic and specific serotonergic antidepressant Mirtazapine Mianserin
    Fugger, Gernot
    Bartova, Lucie
    Fabbri, Chiara
    Fanelli, Giuseppe
    Zanardi, Raffaella
    Dold, Markus
    Kautzky, Alexander
    Rujescu, Dan
    Souery, Daniel
    Mendlewicz, Julien
    Zohar, Joseph
    Montgomery, Stuart
    Serretti, Alessandro
    Kasper, Siegfried
    JOURNAL OF AFFECTIVE DISORDERS, 2022, 312 : 225 - 234
  • [26] Antidepressant medication exposure and 5-HT1A autoreceptor binding in major depressive disorder
    Metts, A. V.
    Rubin-Falcone, H.
    Ogden, R. T.
    Lin, X.
    Wilner, D. E.
    Burke, A. K.
    Sublette, M. E.
    Oquendo, M. A.
    Miller, J. M.
    Mann, J. J.
    SYNAPSE, 2019, 73 (06)
  • [27] Effects of Antidepressant Medication on Emotion Regulation in Major Depressive Disorder: An iSPOT-D Report
    Williams, Leanne
    McRae, Kateri
    Rekshan, William
    Gross, James
    NEUROPSYCHOPHARMACOLOGY, 2013, 38 : S391 - S391
  • [28] The Antidepressant Treatment Response Index as a Predictor of Reboxetine Treatment Outcome in Major Depressive Disorder
    Caudill, Marissa M.
    Hunter, Aimee M.
    Cook, Ian A.
    Leuchter, Andrew F.
    CLINICAL EEG AND NEUROSCIENCE, 2015, 46 (04) : 277 - 284
  • [29] Effectiveness and cost-effectiveness of antidepressant treatment in primary health care:: A six-month randomised study comparing fluoxetine to imipramine
    Serrano-Blanco, A
    Gabarron, E
    Garcia-Bayo, I
    Soler-Vila, M
    Caramés, E
    Peñarrubia-Maria, MT
    Pinto-Meza, A
    Haro, JM
    JOURNAL OF AFFECTIVE DISORDERS, 2006, 91 (2-3) : 153 - 163
  • [30] Social and occupational functioning impairment in patients in partial versus complete remission of a major depressive disorder episode. A six-month prospective epidemiological study
    Romera, I.
    Perez, V.
    Menchon, J. M.
    Delgado-Cohen, H.
    Polavieja, P.
    Gilaberte, I.
    EUROPEAN PSYCHIATRY, 2010, 25 (01) : 58 - 65